These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 526008)

  • 1. Mezlocillin pharmacokinetics in patients with normal and impaired renal functions.
    Bergan T; Brodwall EK; Wiik-Larsen E
    Antimicrob Agents Chemother; 1979 Nov; 16(5):651-4. PubMed ID: 526008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.
    Kampf D; Schurig R; Weihermüller K; Förster D
    Antimicrob Agents Chemother; 1980 Jul; 18(1):81-7. PubMed ID: 6448024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.
    Frimodt-Möller N; Maigaard S; Toothaker RD; Bundtzen RW; Brodey MV; Craig WA; Welling PG; Madsen PO
    Antimicrob Agents Chemother; 1980 Apr; 17(4):599-607. PubMed ID: 6446877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of temocillin (BRL 17421) in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Fillastre JP; Borsa F; Godin M
    J Antimicrob Chemother; 1983 Jul; 12(1):47-58. PubMed ID: 6619046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination kinetics of mezlocillin in normal and impaired renal function including the effects of dialysis.
    Kosmidis J; Doundoulaki P; Stathakis C; Zerefos N; Bounia A; Daikos GK
    Arzneimittelforschung; 1979; 29(12a):1960-2. PubMed ID: 543901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of azlocillin in persons with normal and impaired renal functions.
    Fiegel P; Becker K
    Antimicrob Agents Chemother; 1978 Sep; 14(3):288-91. PubMed ID: 708008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the new broad spectrum penicillin CP-33994-2.
    Bergan T; Brodwall EK; Orjavik O
    Arzneimittelforschung; 1980; 30(7):1144-7. PubMed ID: 7191297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics of intravenous mezlocillin in patients with normal and impaired renal function (author's transl)].
    Cano JP; Rigault JP; Gevaudan MJ; Saingra S; Murisasco A; Charpin J
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):335-9. PubMed ID: 6460972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of acylureidopenicillin pharmacokinetics.
    Bergan T
    Scand J Infect Dis Suppl; 1981; 29():33-48. PubMed ID: 7031864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mezlocillin pharmacokinetics in renal impairment.
    Aronoff GR; Sloan RS; Luft FC; Nelson RL; Maxwell DR; Kleit SA
    Clin Pharmacol Ther; 1980 Oct; 28(4):523-8. PubMed ID: 6447570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the pharmacokinetics and dose dependency of azlocillin in normal subjects and patients with renal insufficiency.
    Bergan T
    J Antimicrob Chemother; 1983 May; 11 Suppl B():101-14. PubMed ID: 6352598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of azlocillin in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Godin M; Fillastre JP
    Antimicrob Agents Chemother; 1980 Mar; 17(3):344-9. PubMed ID: 7425600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function.
    Kampf D; Borner K; Möller M; Kessel M
    Clin Pharmacol Ther; 1984 Feb; 35(2):214-20. PubMed ID: 6319069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function.
    Brogard JM; Comte F; Spach MO; Lavillaureix J
    Chemotherapy; 1982; 28(5):318-26. PubMed ID: 6216076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent pharmacokinetics of mezlocillin in subjects with normal and impaired renal function.
    Mangione A; Janicke DM; Boudinot FD; Schultz RM; Jusko WJ
    J Antimicrob Chemother; 1982 Jan; 9 Suppl A():81-5. PubMed ID: 6210686
    [No Abstract]   [Full Text] [Related]  

  • 16. Interactions between mezlocillin and sisomicin in vitro and in patients with normal and various degrees of impaired renal function.
    Kampf D; Schurig R; Bergs A; Förster D
    Clin Nephrol; 1983 Jan; 19(1):37-44. PubMed ID: 6219847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of azlocillin in healthy subjects.
    Leroy A; Humbert G; Fillastre JP
    Scand J Infect Dis Suppl; 1981; 29():49-54. PubMed ID: 6947405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical pharmacokinetics of azlocillin].
    Singlas E; Haegel C
    Presse Med; 1984 Mar; 13(13):788-96. PubMed ID: 6231596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of temocillin in patients with normal and impaired renal function.
    Boelaert J; Daneels R; Schurgers M; Lambert AM; Van Landuyt HW; Mellows G; Wolf J; Swaisland AJ
    J Antimicrob Chemother; 1983 Apr; 11(4):349-56. PubMed ID: 6853404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of piperacillin dose on elimination kinetics in renal impairment.
    Aronoff GR; Sloan RS; Brier ME; Luft FC
    Eur J Clin Pharmacol; 1983; 24(4):543-7. PubMed ID: 6222908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.